Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Commodity expert looks at deflation, gold and energy


Bookmark and Share

 "Deflation is the absolute worst environment for investors because all assets decline sharply and economic activity grinds to a halt," says Eric Roseman.

In his Commodity Trends Alert he adds, "Every sector of the commodity complex has tanked, including a few areas that I believe should be appreciating because of bullish demand." Here's his outlook and top picks in the oil and gold sectors.

"Global growth forecasts are being revised lower virtually daily. Until we transition from an environment of rapidly falling prices, commodities, stocks, bonds (except Treasury debt) and real estate will continue to decline sharply in value.

"I suspect the global central banks and government authorities will continue to throw everything they’ve got at this crisis until prices stop sliding.

Advertisement
Banner

"This will include trillions more in bailouts, the nationalization of banking and a wave of interest rate cuts. Not one corner of the globe is safe. Everyone is in this together.

"I have to confess to never witnessing anything like this before; almost daily, commodities are following stocks to the basement and hitting new lows. The market is starving for liquidity and everyone is running into dollars. Cash is king.

"Gold has been a first-class disappointment amid bank failures, bailouts, credit collapses, etc. This should have been the year for gold. The rapid desperate flight to liquidity has hurt gold because investors want cash – nothing else.

"It’s the race to cash that has pricked gold. Yet, there’s no other way to save the financial system as we know it other than printing like mad.

"t will take time, but over the next 12-18 months the Fed and other central banks will arrest deflation; gold will recover and so will the gold stocks long before deflation peaks.

"I’m still buying the gold stocks in this wreck. I added to my existing positions in Goldcorp (NYSE: GG), Silver-Wheaton (NYSE: SLW), Kinross Gold (NYSE: KGC) and Barrick Gold (NYSE: ABX). These stocks now trade at three-year low and in some cases, five-year lows."

"I’m also a long-term energy bull. So I therefore ask myself if I don’t buy the major oil companies now at these distressed levels accompanied by fat dividends, then when?

"The oil stocks are trading right at the basement. I’m holding and accumulating ENI (NYSE: ENI) of Italy, France’s Total (NYSE: TOT) and Russia’s Lukoil (Other OTC: LUKOY).

"All three stocks trade as ADRs in New York, sell at multi-year lows and pay dividends. Lukoil, the world’s most undervalued major oil concern, has been ripped to shreds by the Russian stock market collapse and crude’s 50% plunge.

"Within these commodity sectors, over the next 12-18 months, we’re going to wake-up and find some of the most compelling values in stocks since the mid-1930s. We’re almost there now. The stock market and commodities, at some point, will find a bottom, if only an intermittent low."


Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary